Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2016 Leerink Global Healthcare Conference
February 04 2016 - 6:30AM
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that it will participate
in a fireside chat at the 2016 Leerink Global Healthcare Conference
taking place Thursday, February 11, 2016 at 2:15 PM Eastern Time.
Investors interested in arranging a meeting with the Company's
management during this conference should contact the conference
coordinator.
The fireside chat will be webcast live and may be accessed from
the Event Calendar page of Sucampo's website at
http://www.sucampo.com/investors/events-presentations/. A replay of
the webcast will also be available on the Company's website for
several days after the live event. To ensure a timely connection,
it is recommended that users register at least 15 minutes prior to
the scheduled webcast.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is focused on the development and
commercialization of medicines that meet major unmet medical needs
of patients worldwide. Sucampo has one marketed product – AMITIZA –
and a pipeline of product candidates in clinical development. A
global company, Sucampo is headquartered in Rockville, Maryland,
and has operations in Japan, Switzerland and the U.K. For more
information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of
Innovation, are registered trademarks of Sucampo AG. AMITIZA is a
registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow
us on LinkedIn (Sucampo Pharmaceuticals).
Twitter LinkedIn
Sucampo Forward-Looking
Statement
This press release contains "forward-looking
statements" as that term is defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations and involve risks and
uncertainties, which may cause results to differ materially from
those set forth in the statements. The forward-looking statements
include statements regarding Sucampo’s option agreement with CPP,
including financial terms of a potential license agreement, and the
expected timing of clinical trials. The following factors, among
others, could cause actual results to differ from those set forth
in the forward-looking statements: the impact of pharmaceutical
industry regulation and health care legislation; the ability of
Sucampo to successfully develop and commercialize product
candidates; Sucampo's ability to accurately predict future market
conditions; and the exposure to litigation and/or regulatory
actions.
No forward-looking statement can be guaranteed
and actual results may differ materially from those projected.
Sucampo undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this
press release should be evaluated together with the many
uncertainties that affect Sucampo's business, particularly those
mentioned in the risk factors and cautionary statements in
Sucampo's most recent Form 10-K as filed with the Securities and
Exchange Commission on March 9, 2015 as well as its filings with
the Securities and Exchange Commission on Forms 8-K and 10-Q since
the filing of the Form 10-K, all of which Sucampo incorporates by
reference.
Contact:
Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Apr 2023 to Apr 2024